Human Ovarian Follicular Dynamics and Emergency Contraception
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The researchers hypothesize that emergency contraception (EC) will initiate the changes associated with atresia or ovulatory failure at all stages of follicular development and that the image attributes associated with atresia will be similar regardless of the diameter of the dominant follicle when ovarian suppression is initiated. Second, changes associated with atresia may be observed, but ovulation of the dominant follicle is unimpeded.
This study is a single-center, randomized, open-label, double-controlled protocol to study the pattern of ovarian follicular growth and regression in two groups of women. The first group will use Plan B, which is a progesterone only OC containing 0.75 levonorgestrel. The second group of women will use the Yuzpe regimen, which uses 50 mg ethinyl estradiol/0.5 mg levonorgestrel pills at different stages of the menstrual follicular cycle.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 40 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Female volunteers of childbearing potential;
Are first time users of oral contraception (OC) or have discontinued OC at least 1 month prior to study entry;
Age between 18 and 40 years old;
Normal body mass index (18-38);
Has signed informed consent form; and
Is in good health as confirmed by medical history, physical examination.
A positive pregnancy test will automatically exclude the volunteer from participation in this study.
Any contraindication for oral contraception use;
Irregular menstrual cycles;
Ultrasonographic evidence of ovarian dysfunction, such as polycystic ovary syndrome (PCOS);
Pregnancy (suspected or diagnosed) or lactation;
History or suspicion of drug or alcohol abuse;
Participation in an investigational drug trial within the 30 days prior to selection;
Exhibits a disorder that is a contraindication to steroid hormonal therapy, including, for example, the following conditions:
history of, or actual, thrombophlebitis or thromboembolic disorders.
history of, or actual, cerebrovascular disorders.
history of, or actual, myocardial infarction or coronary artery disease.
acute liver disease.
history of, or actual, benign or malignant liver tumors.
history of, or suspected, carcinoma of the breast.
known, or suspected, estrogen-dependent neoplasia.
undiagnosed abnormal vaginal bleeding.
any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual field.